/
International Stem Cell Corporation (sometimes referred to herein as ISCO , the Company , we , us , or our ) is a clinical stage biotechnology company focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities and two revenue-generating businesses offering potential for increased future revenue. We currently have no revenue generated from our pri…
The business is unprofitable at the operating level (-2.93% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue growth slowed to 0.2%, essentially flat. Margins also contracted 2.2pp. This is a business that needs a catalyst.
ROIC dropped from -1.34% to -5.57%, capital efficiency is deteriorating. Negative free cash flow of -$35K. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$9M
▲ +0.2% YoY
Net Income (TTM)
-$382K
▼ -100.0% YoY
Op. Margin
-2.61%
▼ -2.2pp YoY
ROIC
-5.14%
▼ -4.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$159K
▲ +77.1% YoY
Op. Cash Flow (TTM)
-$98K
▼ -38.5% YoY
Net Debt
$3M
Cash & Equiv.
$933K
5Y CAGR: +5.0%
Continue Research